US FDA approves Replimune's skin cancer drug
06/08/2026 21:13
US FDA approves Replimune's skin cancer drug Aug 6 (Reuters) - The U.S. Food and Drug Administration has approved Replimune's REPL.O drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product after years of regulatory setbacks.
(Reporting by Kamal Choudhury and Sneha S K in Bengaluru; Editing by Vijay Kishore)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly